CalciMedica, Inc. (CALC) stock
CALCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.22+0.03 (+2.52%)
Close on Nov 17, 2026Market cap $41.65MP/E –Yield –
CalciMedica r&d expenses
Research and development expenses are spending on new products and technology.
CalciMedica's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.55M, down 19.9% year over year. For fiscal 2025 it was $15.23M, up 5.2% from the year before. The highest annual figure on record is $30.58M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.23M | +5.2% |
| FY2024 | Dec 31, 2024 | $14.48M | -8.7% |
| FY2023 | Dec 31, 2023 | $15.86M | +89.9% |
| FY2022 | Dec 31, 2022 | $8.35M | -55.8% |
| FY2021 | Dec 31, 2021 | $18.90M | -9.8% |
| FY2020 | Dec 31, 2020 | $20.96M | -31.5% |
| FY2019 | Dec 31, 2019 | $30.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.10M | -48.1% |
| Q1 FY2026 | Mar 31, 2026 | $3.49M | -17.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.11M | -18.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.85M | +8.6% |
| Q2 FY2025 | Jun 30, 2025 | $4.05M | -2.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.22M | +43.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.83M | +37.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.55M | +27.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.16M | +9.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.94M | -54.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.78M | +23.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.77M | -5.2% |
| Q2 FY2023 | Jun 30, 2023 | $3.81M | -10.6% |
| Q1 FY2023 | Mar 31, 2023 | $6.49M | +61.4% |
| Q2 FY2022 | Jun 30, 2022 | $2.26M | -45.8% |
| Q1 FY2022 | Mar 31, 2022 | $2.93M | -54.6% |
| Q4 FY2021 | Dec 31, 2021 | $4.27M | -22.2% |
| Q3 FY2021 | Sep 30, 2021 | $4.02M | -15.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.17M | -10.1% |
| Q1 FY2021 | Mar 31, 2021 | $6.45M | +6.0% |
| Q4 FY2020 | Dec 31, 2020 | $5.49M | -31.5% |
| Q3 FY2020 | Sep 30, 2020 | $4.76M | -43.4% |
| Q2 FY2020 | Jun 30, 2020 | $4.63M | – |
| Q1 FY2020 | Mar 31, 2020 | $6.09M | – |
| Q4 FY2019 | Dec 31, 2019 | $8.01M | – |
| Q3 FY2019 | Sep 30, 2019 | $8.40M | – |
See a number that looks wrong?